Cue Biopharma: A High-Stakes Investment With 400% Upside Potential

Cue Biopharma presents investors with a dramatic dichotomy. While market analysts project share price appreciation exceeding 400%, the company’s own leadership has issued a stark warning regarding substantial doubt over its ability to continue operating.

At the Cantor Global Healthcare Conference on September 5, Chief Executive Officer Daniel Passeri highlighted key developments within the company’s Immuno-STAT® platform. The presentation placed particular emphasis on CUE-401, its lead autoimmune asset, which is designed to deliver selective T-cell modulation for treating autoimmune conditions.

Second Quarter 2025 Financial Performance

The financial results released on August 12 painted a nuanced picture of the company’s position:
* Collaboration revenue reached $3.0 million, up from $2.7 million in the prior-year period
* Research and development expenditures decreased... Read more...